Extended Data Fig. 2: PSME4 is increased in NSCLC and stratifies response.
a,b, Kaplan-Meier curves of patient survival stratified by the ratio in expression between PSME4 and PSME1 for the melanoma cohorts treated with immunotherapy (SKCM ICI, a) or bladder cancer (BLCA ICI, b). Significance determined from Log-ranked test. c, Patients were stratified by PSME1 expression in the ICI cohorts and the response rate for the PSME1-low and PSME1-high groups are shown. PSME1 alone does not consistently categorize a response status among the cancer types analyzed. d, Kaplan-Meier curves of patient survival stratified by the regulatory subunit clusters defined in ‘Fig. 1c’ for the TCGA cohorts. Significance determined from Log-ranked test (n = 9724 tumors). e, H&E staining of tumor or adjacent tissue from 2 representative patients (Scale bar represent 2000 µm.). f, Immunohistochemistry staining for PSME4 of tumor or adjacent tissue from 3 representative patients (Scale bar represent 2000 µm (X0.5), 100 µm (X10) and 20 µm (X40)). g, Immunoblotting band intensity across tumor or adjacent tissues were quantified for PSME4 and normalized to actin as a loading control (two-sided paired student’s t-test *P = 0.0437, n = 5 patients). h, Immunoblotting band intensity across tumor or adjacent lung tissues from an independent cohort were quantified for PSME4 and normalized to actin as a loading control (two-sided paired student’s t-test **P = 0.01, n = 6 patients).
